Recently, according to media reports, the State Administration of Pharmaceutical Products has approved the application of Xiamen Wan Tai Canghai Biotechnology Co., Ltd. for listing and registration of bivalent human papillomavirus vaccine, which is the first approved human papillomavirus vaccine in China and is suitable for women aged 9-45.
The report pointed out that this vaccine is the first cervical cancer vaccine independently developed by China, which was jointly developed by Wan Tai Company and Xiamen University and transformed by Wan Tai. It will become the third HPV vaccine approved in the world and the first in China, which means that the cervical cancer vaccine in China can only be imported.
Human papillomavirus vaccine, commonly known as cervical cancer vaccine, can be used to prevent female cervical cancer, male and female genital cancer and genital warts. At present, there are three kinds of human papillomavirus vaccines on the international market, namely, bivalent vaccines against human papillomavirus 16 and 18 produced by GlaxoSmithKline, UK, and anti-HPV6, 1 1 6 and 18 produced by Merck, USA.
According to statistics, cervical cancer caused by human papillomavirus is the fourth most common cancer in women. In 20 18, there were about 570,000 new cases of cervical cancer and about 3 1. 1 10,000 deaths worldwide.
The bivalent human papillomavirus vaccine approved this time is aimed at human papillomavirus HPV 16 and 18, and has been included in the special support of national major new drug creation. After being approved for listing, it will further meet the needs of the public and improve the accessibility of products.
Learn more about breaking the monopoly! More domestic HPV vaccines have been officially approved as the third in the world. Please continue to pay attention to the column of deep space science and technology information, and Bian Xiao will continue to update more scientific and technological information for you. Heart of the King 2 Click on the demo.